NCT04982848View on ClinicalTrials.gov

Korea Post Marketing Surveillance (PMS) Study of Talzenna®

Not yet recruitingOBSERVATIONAL

Enrollment

600

Participants

Timeline

Start Date

December 31, 2025

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2026

Conditions

Breast Neoplasms

Interventions

DRUG

Talzenna

Talzenna treatment under Korea regulatory approval indication/dosage

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Pfizer

INDUSTRY